Comparison of the pharmacological properties of classical and novel BZ-ω receptor ligands

Behavioural Pharmacology

Volumn 10, Issue 5, 1999, Pages 483-495

  Griebel, G ^a   Perrault, G ^a   Tan, S ^a   Schoemaker, H ^a   Sanger, D J ^a  

^a SANOFI   (France)

Author keywords

Abecarnil; Anxiety; Ataxia; Benzodiazepines; Binding; Convulsions; Imidazenil; Mouse; Myorelaxation; Omega receptors; Rat; RWJ 46771; SX 3228; Y 23684

Indexed keywords

1,6 NAPHTHYRIDIN 5 ONE DERIVATIVE; 2 (4 CHLOROPHENYL) 5,6 DIHYDRO [1]BENZOTHIEPINO[5,4 C]PYRIDAZIN 3(2H) ONE 7 OXIDE; ABECARNIL; BENZIMIDAZOLE DERIVATIVE; BENZODIAZEPINE OMEGA RECEPTOR; BENZODIAZEPINE RECEPTOR; BETA CARBOLINE; BRETAZENIL; CLOBAZAM; DIAZEPAM; FLUMAZENIL; IMIDAZENIL; PYRIDAZINONE DERIVATIVE; RECEPTOR SUBTYPE; RWJ 46771; SX 3228; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; ATAXIA; CEREBELLUM; CLONIC SEIZURE; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EXPLORATORY BEHAVIOR; INTRAPERITONEAL DRUG ADMINISTRATION; LATENT PERIOD; LOCOMOTION; MALE; MAZE TEST; MOTOR PERFORMANCE; MOUSE; MUSCLE RELAXATION; NONHUMAN; RAT; SEDATION; SPINAL CORD; SUBCUTANEOUS DRUG ADMINISTRATION; TRANQUILIZING ACTIVITY;

EID: 0032841771     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199909000-00007     Document Type: Article

References (46)

1. Braestrup C, Nielsen M (1980). Multiple benzodiazepine receptors. Trends Neurosci 3:301-303.
2. Cole JC, Rodgers RJ (1993). An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 166028) in the murine elevated plusmaze. Behav Pharmacol 4:573-580.
3. Depoortere H, Zivkovic B, Lloyd KG et al. (1986). Zolpidem, a novel nonbenzodiazepine hypnotic: I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 237:649-658.
4. A receptors. J Pharmacol Exp Ther 266:1018-1028.
5. Griebel G, Sanger DJ, Perrault G (1996a). The use of the rat elevated plusmaze to discriminate between non selective and BZ1 (ω) selective, benzodiazepine receptor ligands. Psychopharmacology (Berl) 124:245-254.
6. Griebel G, Sanger DJ, Perrault G (1996b). Further evidence for differences between nonselective and BZ1 (ω) selective, benzodiazepine receptor ligands in murine models of 'state' and 'trait' anxiety. Neuropharmacology 35:1081-1091.
7. Griebel G, Rodgers RJ, Perrault G, Sanger DJ (1997). Risk assessment behaviour: Evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacol Biochem Behav 57:817-827.
8. Griebel G, Perrault G, Sanger DJ (1998). Limited anxiolyticlike effects of nonbenzodiazepine hypnotics in rodents. J Psychopharmacol 12:356-365.
9. Jones GH, Schneider C, Schneider HH, Seidler J, Cole BJ, Stephens DN (1994). Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: An analysis based on fractional receptor occupancies. Psychopharmacology (Berl) 114:191-199.
10. A receptor. J Pharmacol Exp Ther 266:385-391.
11. Lader M (1994). Benzodiazepines: a risk-benefit profile. CNS Drugs 1:377-387.
12. Langer SZ, Arbilla S (1988). Imidazopyridines as a tool for the characterization of benzodiazepine receptors: a proposal for a pharmacological classification as omega receptor subtypes. Pharmacol Biochem Behav 29:763-766.
13. Langer SZ, Arbilla S, Benavides J, Scatton B (1990). Zolpidem and alpidem: two imidazopyridines with selectivity for ω1 and ω3 receptor subtypes. Adv Biochem Psychopharmacol 46:61-72.
14. Löscher W, Frey HH (1977). Effect of convulsant and anticonvulsant agents on level and metabolism of gamma-aminobutyric acid in mouse brain. Naunyn Schmiedebergs Arch Pharmacol 296:263-269.
15. A benzodiazepine receptor heterogeneity: neurophysiological implications. Neuropharmacology 34:245-254.
16. Mao CC, Guidotti A, Costa E (1975). Evidence for an involvement of GABA in the mediation of the cerebellar cGMP decrease and the anticonvulsant action diazepam. Naunyn Schmiedebergs Arch Pharmacol 289:369-378.
17. Martin JR, Pieri L, Bonetti EP et al. (1988). Ro 166028: a novel anxiolytic acting as a partial agonist at the benzodiazepine receptor. Pharmacopsychiatry 21:360-362.
18. Maryanoff BE, Ho W, McComsey DF et al. (1995). Potential anxiolytic agents. Pyrido[1,2 alpha]benzimidazoles: A new structural class of ligands for the benzodiazepine binding site on GABAA receptors. J Med Chem 38:16-20.
19. Ohta T (1996). Recent progress in development of psychotropic drugs (5) Hypnotics. Jpn J Psychopharmacol 16:161-170.
20. Fellow S, Chopin P, File SE, Briley M (1985). Validation of open:closed arm entries in an elevated plusmaze as a measure of anxiety in the rat. J Neurosci Meth 14:149-167.
21. Perrault G, Morel E, Sanger DJ, Zivkovic B (1990). Differences in pharmacological profiles of a new generation of benzodiazepine and nonbenzodiazepine hypnotics. Eur J Pharmacol 187:487-494.
22. Perrault G, Morel E, Sanger DJ, Zivkovic B (1992). Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J Pharmacol Exp Ther 263:298-303.
23. A receptor subtypes. In: Anxiolytic ß-Carbolines. Stephens DN (editor). Berlin: Springer, pp. 50-61.
24. A/ benzodiazepine receptor complex in the rat nervous system. J Neurochem 58:485-493.
25. Sanger DJ (1995). The behavioural effects of novel benzodiazepine (ω) receptor agonists and partial agonists: Increases in punished responding and antagonism of the pentylenetetrazole cue, Behav Pharmacol 6:116-126.
26. Sanger DJ, Joly D and Zivkovic B (1985). Behavioral effects of nonbenzodiazepine anxiolytic drugs: a comparison of CGS 9896 and zopiclone with chlordiazepoxide. J Pharmacol Exp Ther 232:831-837.
27. Sanger DJ, Benavides J, Perrault G et al. (1994). Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: Evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 18:355-372.
28. Sanger DJ, Joly D, Perrault G (1995). Benzodiazepine (ω) receptor partial agonists and the acquisition of conditioned fear in mice. Psychopharmacology (Berl) 121:104-108.
29. Schocmaker H, Claustre Y, Fage D et al. (1997). Neurochemical characteristics of amisulpride, an atypical dopamine D2/ D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83-97.
30. Serra M, Ghiani CA, Motzo C, Purceddu ML, Biggio G (1994a). Long-term treatment with abecarnil fails to induce tolerance in mice. Eur J Pharmacol 259:1-6.
31. A receptor function. J Pharmacol Exp Ther 269:32-38.
32. A receptor subtypes. Pharmacol Rev 47:181-234.
33. Sighart W, Schuster A (1984). Affinity of various ligands for benzodiazepine receptors in rat cerebellum and hippocampus. Pharmacol Biochem Behav 33:4033-4038.
34. Squires RF, Benson DI, Braestrup C et al. (1979). Some properties of brain specific benzodiazepine receptors: new evidence for multiple receptors. Pharmacol Biochem Behav 10:825-830.
35. Stephens DN, Voet B (1994). Differential effects of anxiolytic and nonanxiolytic benzodiazepine receptor ligands on performance of a differential reinforcement of low rate (DRL) schedule. Behav Pharmacol 5:4-14.
36. Stephens DN, Schneider HH, Kehr W et al. (1990). Abecarnil, a metabolically stable, anxioselective betacarboline acting at benzodiazepine receptors. J Pharmacol Exp Ther 253:334-343.
37. 5-containing omega/benzodiazepine receptor subtype in rat brain. Can J Physiol Pharmacol 72:448.
38. Turski L, Stephens DN, Jensen LH et al. (1990). Anticonvulsant action of the betacarboline abecarnil: studies in rodents and baboon, Papio papio. J Pharmacol Exp Ther 253:344-352.
39. Vogel JR, Beer B, Clody DE (1971). A simple and reliable conflict procedure for testing antianxiety agents. Psychopharmacologia 21:1-7.
40. Wafford KA, Whiting PJ, Kemp JA (1993). Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant gamma-aminobutyric acid receptor subtypes. Mol Pharmacol 43:240-244.
41. Yakushiji T, Shirasaki T, Munakata M, Hirata A, Akaike N (1993). Differential properties of type I and type II benzodiazepine receptors in mammalian CNS neurones. Br J Pharmacol 109:819-825.
42. Yasumatsu H, Morimoto Y, Yamamoto Y et al. (1994). The pharmacological properties of Y23684, a benzodiazepine receptor partial agonist. Br J Pharmacol 111:1170-1178.
43. Yasumatsu H, Asano K, Morio Y, Matsumoto Y, Takehara S (1998). Anxioselective pharmacological property of Y23684, a benzodiazepine receptor (BZR) partial agonist: a comparison with other BZR agonists. In: XXIst CINP Congress, Glasgow (Abstract).
44. Zivkovic B, Perrault G, Morel E, Sanger DJ (1988). Comparative pharmacology of zolpidem and other hypnotics and sleep inducers. In: Imidazopyridines in Sleep Disorders. Sauvanet JP, Langer SZ, Morselli PL (editors). New York: Raven Press.
45. Zivkovic B, Morel E, Joly D, Perrault G, Sanger DJ, Lloyd KG (1990). Pharmacological and behavioral profile of alpidem as an anxiolytic. Pharmacopsychiatry, 23 (Suppl. 3): 108-113.
46. Zivkovic B, Perrault G, Sanger D (1992). Receptor subtype-selective drugs: a new generation of anxiolytics and hypnotics. In: Target Receptors for Anxiolytics and Hypnotics: From Molecular Pharmacology to Therapeutics. Mendlewitz J, Racagni G (editors). Basel: Karger, pp. 55-73.